Tag: ACR Convergence 2026

Johnson & Johnson headquarters in New Brunswick, New Jersey — the company behind ICOTYDE (icotrokinra), which met its main goal in a Phase 3 psoriatic arthritis trial. Photo: Wikimedia Commons / ajay_suresh, CC BY 4.0, taken 10 March 2026.

Health

Johnson & Johnson’s Once-Daily Pill Eases Psoriatic Arthritis in Late-Stage Trial, Offering Hope of an Injection-Free Option

6 minutes ago 17 min read

Johnson & Johnson says its once-daily pill ICOTYDE met its main goal in a 552-patient Phase 3 trial,…